Points to Consider for the Design of Clinical Trials to Assess the Effects of Psychotropic Drugs on Driving Performance — PMDA Early Consideration Summary

In Plain Language

The document addresses how clinical trials can assess whether psychotropic drugs affect a person's ability to drive. Sedation-related effects, such as drowsiness, may be more common early in treatment or when a dose is increased, so the assessment should consider not only whether an effect occurs but also whether it is clinically meaningful and how long it persists. The document points to a step-by-step approach: use the information gathered about the investigational drug to decide which studies are appropriate, rather than automatically conducting every type of study, including driving studies. If a driving study is conducted because existing nonclinical and clinical information suggests an effect, the study should assess the size and persistence of that effect. The aim is to support appropriate assessment of risk and precautions while contributing to the appropriate use of treatments.

What This Guidance Covers

The document, titled Points to Consider for the Design of Clinical Trials to Assess the Effects of Psychotropic Drugs on Driving Performance, focuses on important aspects of clinical-trial design for evaluating the effects of psychotropic drugs on driving performance. It is not presented as a complete protocol or as a set of universal study requirements. Instead, it explains considerations for deciding how to evaluate a particular investigational drug and what to examine when assessing driving-related impairment.

For this document, “psychotropic drugs” has a specific meaning. It does not mean psychotropic drugs as defined in Japan's Narcotic Drugs and Psychotropic Substances Control Act. It refers to drugs classified in the Japan Standard Commodity Classification under the categories listed in the document: hypnotics and sedatives, antianxietics (112), antiepileptics (113), psychotropic agents (117), and other agents affecting the central nervous system (119). The last group includes drugs for the treatment of insomnia, narcolepsy, and attention-deficit/hyperactivity disorder.

The document concerns assessment of effects on driving performance, with particular attention to sedative side effects that affect alertness, including drowsiness. It discusses the role of exploratory, validation, and long-term studies in evaluating the profile of adverse events affecting driving, as well as the circumstances in which driving studies may be considered. It does not set out detailed trial designs, numerical thresholds, or specific analytical procedures in the text provided.

Why It Matters

The document describes two connected aims: protecting patient safety through appropriate precautions about driving-related effects, and supporting opportunities to provide appropriate therapeutic drugs. It notes that recent psychotropic drugs have been shown to reduce sedative side effects, making them more tolerable. Assessing their effects on driving is therefore relevant both to understanding potential impairment and to informing precautions for patients.

A key challenge is that the effect may not be constant throughout treatment. The document says sedative side effects affecting alertness, such as drowsiness, are observed more frequently during initial treatment stages and dose escalation. A study or assessment focused only on one moment could therefore fail to describe how the effect changes over time. The document identifies the issue as assessing whether an effect is clinically meaningful and whether that impairment persists.

The document also situates its considerations in the context of a Japanese Ministry of Health, Labour and Welfare (MHLW) guideline for evaluating the effects of psychotropic drugs on motor vehicle driving performance. As described here, that guideline recommends a tiered approach and appropriate evaluation of the profile of adverse events affecting driving in exploratory, validation, and long-term studies. The document's response is to emphasize stepwise evaluation and selection of proposed studies based on the investigational drug's profile, rather than treating every possible study as automatically necessary.

Key Recommendations

1. Assess the drug profile step by step. The document says that, in line with the tiered approach recommended in the MHLW guideline, it is appropriate to evaluate the profile of the investigational drug in stages and identify the studies needed. It specifically cautions against proceeding as though all studies indicated in the guideline, including driving studies, should be conducted in every case.

2. Evaluate adverse events affecting driving across relevant study stages. The document states that the MHLW guideline recommends appropriate evaluation of the profile of adverse events affecting driving in exploratory, validation, and long-term studies. This is important because the document highlights that effects on alertness may be more frequent during early treatment or dose escalation. The text does not prescribe a particular schedule or measurement instrument for these evaluations.

3. Consider whether impairment is clinically meaningful and persistent. The central assessment issue is not simply whether a sedative side effect is reported. It is whether side effects affecting alertness, such as drowsiness, have a clinically meaningful effect on driving performance and whether that effect persists. The document refers to this as the “persistence of clinically meaningful impairment.”

4. Examine drug exposure alongside the timing of relevant adverse events. To assess persistence of clinically meaningful impairment, the document recommends examining the blood concentration of the investigational drug and its active metabolite, together with the temporal relationship of adverse events affecting driving. The timing information includes onset, duration, and tolerance.

5. If a driving study is conducted, assess both magnitude and persistence. This point applies when accumulated information from nonclinical and clinical studies suggests an effect on driving performance and driving studies are conducted. In that situation, the document says it is important to assess the magnitude of the effect as well as how persistent it is. It does not state that a driving study is automatically indicated whenever the drug belongs to one of the listed categories.

Practical Implications

Interpretation: For development teams, the tiered approach makes the drug-specific evidence central to planning. Teams can organize the available nonclinical and clinical information, consider what it suggests about driving performance, and use that profile to identify proposed next studies. The document's point is not to assume that a single study type answers every question, nor to conduct the full set of studies without regard to the information already available.

Interpretation: Study planning should keep the treatment timeline in view. Because the document highlights initial treatment and dose escalation as periods when alertness-related sedative side effects are more frequently observed, teams may need to consider how their study information describes those periods. This is an implication of the timing issue raised in the document, not a specified requirement for particular visit schedules or dose regimens.

Interpretation: Clinical, safety, and pharmacokinetic teams have related information to bring together. Blood concentrations of the investigational drug and active metabolite provide exposure information; adverse-event records provide information about when relevant effects begin, how long they last, and tolerance. Considering these together can help characterize whether an effect changes over time. The document does not prescribe a particular statistical model or a numerical definition of clinically meaningful impairment.

Interpretation: Teams should distinguish between evaluating adverse events that may affect driving in the broader clinical program and conducting a driving study. The document refers to the former across exploratory, validation, and long-term studies, while describing driving studies conditionally: they are relevant when accumulated nonclinical and clinical information suggests an effect. If one is conducted, the effect's magnitude and persistence are important aspects to assess.

Technical Details

The document gives a compact framework rather than a detailed statistical method. Its central concept, “persistence of clinically meaningful impairment,” links three kinds of information: whether impairment is meaningful, the time course of adverse events affecting driving, and drug exposure. The relevant adverse events are defined based on the pharmacological and other characteristics of the investigational drug. Accordingly, the specific events considered may depend on the drug; the document does not provide a universal event list.

In practical terms, onset concerns when an event begins, duration concerns how long it continues, and tolerance concerns whether the effect changes with continued exposure. These plain-language descriptions explain the terms; the document does not provide operational criteria for measuring them. The document recommends examining this time-course information alongside blood concentrations of the investigational drug and its active metabolite.

The reasoning can be read as a sequence:

The document refers readers to a recent review article for specific analytical methods for assessing persistence of clinically meaningful impairment. It does not reproduce those methods or give an equation, decision threshold, or numerical rule. Readers should therefore not infer a particular analysis from this summary.

Who Should Read It

This document is relevant to teams developing psychotropic drugs that may affect alertness or driving performance. It may be useful to clinical pharmacologists and statisticians considering exposure and time-course information; clinical operations and safety teams planning how adverse events are captured across study stages; and regulatory affairs and medical writing teams explaining the rationale for proposed evaluations. Investigators and other clinical researchers may also find it useful when considering how driving-related adverse events fit into a drug's clinical development. Its considerations are especially pertinent when early treatment or dose escalation may be associated with alertness-related sedative effects, or when accumulated nonclinical and clinical information suggests a possible effect on driving.

Official PMDA Source

• Official title: Points to Consider for the Design of Clinical Trials to Assess the Effects of Psychotropic Drugs on Driving Performance (Early consideration)
• Issuing body: Pharmaceuticals and Medical Devices Agency, Office of New Drug Ⅲ
• Date on the document: August 15th, 2024
• PMDA PDF: Official PMDA document (PDF)
• PMDA list page: PMDA Early Consideration documents

Source: Pharmaceuticals and Medical Devices Agency (PMDA) website, PMDA Early Consideration documents. This page was created by editing and summarising the PMDA document.

Consult the official document for the full text; this summary does not replace it. PMDA provides the English version for reference, and the Japanese original prevails if the two differ. PMDA describes Early Consideration documents as reference information reflecting the Agency's views at the time of publication; those views may change as scientific knowledge develops.

Related Clinical Biostats Resources

• All Clinical Biostats tutorials — Browse other educational summaries and tutorials across clinical research and biostatistics topics.
• Statistical Calculators — Access calculators that may assist with statistical work in clinical research.